Operationalizing High-Sensitivity Cardiac Troponin Pathways - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Implementing High-Sensitivity Cardiac Troponin Testing Pathways

  • By

  • James S. Ford

  • William B. Stubblefield

  • Jesse O. Wrenn

  • November 10, 2026

Share

Clinical Scorecard: Implementing High-Sensitivity Cardiac Troponin Testing Pathways

At a Glance

Category

Detail

Condition

Suspected acute myocardial infarction (AMI) in patients presenting to the emergency department (ED) with chest pain or other anginal equivalents.

Key Mechanisms

High-sensitivity cardiac troponin (hs-cTn) assays detect low-level myocardial injury. Increased serial testing may reflect both assay sensitivity and pathway-driven repeat sampling. The reported EHR-integrated pathway used conditional serial orders, shared pathway status and timing, and a final evaluation interpretation.

Target Population

Patients with chest pain who underwent cardiac troponin testing in the ED; the article also discusses patients with other anginal equivalents.

Care Setting

Four urban emergency departments using an EHR-integrated hs-cTn testing pathway.

Key Highlights

  • The Fifth Universal Definition of Myocardial Infarction recommends adding hs-cTn to accelerated diagnostic pathways.

  • An EHR-integrated hs-cTn pathway across four urban EDs was associated with an approximately 30-minute decrease in ED length of stay among patients with chest pain who underwent troponin testing.

  • The greatest reductions in time occurred among patients requiring serial troponin assays; the intervention included conditional serial orders, shared pathway status and timing, and a final evaluation interpretation.

  • The hs-cTn period had more serial troponin measurements and more 30-day AMI diagnoses, without a corresponding rise in 30-day PCI or ED cardiology consultation.

  • The study did not assess patient-centered outcomes such as missed AMI, readmissions, or mortality, and its pre-post design cannot isolate the effects of the assay from the pathway and workflow changes.

Guideline-Based Recommendations

Diagnosis

  • The Fifth Universal Definition of Myocardial Infarction recommends adding hs-cTn to accelerated diagnostic pathways.

  • The article discusses interpreting increased serial testing and additional myocardial injury diagnoses in light of assay sensitivity and pathway-driven repeat sampling.

Management

  • The reported intervention integrated conditional serial orders, shared pathway status and timing, and a final evaluation interpretation into the EHR workflow.

  • The article states that the clinical value of additional diagnoses depends in part on whether they appropriately alter management and improve patient-centered outcomes.

Monitoring & Follow-up

  • The article calls for future research on broader ED crowding measures, including leaving without being seen and time to initial clinician evaluation.

  • The article identifies missed AMI and patient outcomes as important considerations when evaluating hs-cTn pathways.

Risks

  • Greater sensitivity and protocolized serial measurement may increase repeat testing and recognition of myocardial injury.

  • The clinical value of additional diagnoses and the consequences of unnecessary testing remain incompletely characterized.

  • The pre-post design is vulnerable to unmeasured influences and secular trends; the source excerpt is truncated before its full discussion of generalizability.

Patient & Prescribing Data

Patients with chest pain who underwent cardiac troponin testing in the emergency department; the article also discusses other anginal equivalents.

The article concerns diagnostic testing pathways rather than a medication treatment. In the reported study, the hs-cTn pathway was associated with shorter ED length of stay and more 30-day AMI diagnoses; missed AMI, readmissions, and mortality were not assessed.

Clinical Best Practices

  • The reported intervention integrated the hs-cTn pathway into the EHR and clinical workflow.

  • The intervention displayed pathway status and timing, conditionally released serial orders, and incorporated a final evaluation interpretation.

  • The article argues that operational efficiency should be evaluated alongside downstream testing, diagnoses, interventions, and patient outcomes.

  • Interpret the reported findings in light of the pre-post design and the multifaceted intervention.

Related Resources & Content

  1. 2025 ACC/AHA/ACEP/NAEMSP/SCAI, American Heart Association, 2025 — Guideline for the Management of Patients With Acute Coronary Syndromes

  2. MDSpire News, n.d. — Putting a POC Troponin to the Test

  3. MDSpire News, n.d. — Troponin Testing and Early MI Discharge

  4. JAMA Cardiology, n.d. — Early Rule Out of Myocardial Infarction With a Novel High-Sensitivity Cardiac Troponin T Assay

  5. The Lancet, 2026 — Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial

  6. Authors not specified in supplied material, n.d. — Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials

  7. the pathologist — Troponin at the Heart of it

  8. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes

  9. Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial

  10. Performance of 0/1 h versus 0/3 h pathways in patients with suspected myocardial infarction: a systematic review and individual participant data meta-analysis of randomised controlled trials

  11. Putting a POC Troponin to the Test

  12. Troponin Testing and Early MI Discharge

Original Source(s)

Related Content